Project Grant R43HL135969

Federal Grant Award Summary The Children's Hospital of Philadelphia Research Institute received an $888,836 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded August 1, 2025, with completion targeted for May 31, 2029. The research project focuses on developing novel therapeutic approaches for Hemophilia A, an X-linked bleeding disorder caused by Factor VIII (FVIII) deficiency. The initiative aims to...

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), provides $306,870 to Kinetiq Therapeutics LLC, a life science startup in Texas, to conduct proof-of-concept studies on an enzyme replacement therapy (ERT) for Fanconi anemia. Fanconi anemia is a rare inherited disease characterized by bone marrow failure and malignancies. The project aims to demonstrate the feasibility of using an...

Federal Project Grant Award Summary Emory University's Office of Sponsored Programs received a $234,750 project grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded August 1, 2025, with completion targeted for July 31, 2027. This research project examines anti-Factor VIII (FVIII) IgM antibodies and their role in propagating immune responses to Factor VIII in hemophilia A patients. The research aims to...

Summary Versiti Blood Health, Inc. received a $604,301 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective August 1, 2025, with a completion date of April 30, 2029. The award funds research investigating membrane-cytoskeleton interactions in megakaryocytes and platelets, with particular focus on understanding the molecular mechanisms underlying platelet production and function. The research...

Federal Project Grant Award Summary The Children's Hospital of Philadelphia Research Institute received a $636,982 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective August 15, 2025, through May 31, 2030. The award funds a comprehensive research investigation into the proteolytic regulation of Factor VIII (FVIII) before and after activation. The research addresses critical gaps in...

This $395,314 Project Grant, awarded by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) on April 18, 2025, supports research by The Leland Stanford Junior University (Stanford University) to define the key cellular components and early immunological events that mediate Factor VIII immunity. The long-term goal is to develop targeted immunomodulatory therapies that prevent inhibitor formation and induce peripheral Factor VIII tolerance in persons with...

This $181,772 project grant from the National Heart, Lung and Blood Institute will support research into coagulopathy in sepsis patients. The grantee, Beth Israel Deaconess Medical Center, will conduct an ancillary study using viscoelastic monitoring to examine the effects of randomly assigned fluid resuscitation strategies on coagulation parameters in sepsis patients. Specifically, the study aims to: 1) analyze how liberal versus restrictive fluid administration impacts coagulation measurements...

This Project Grant award of $234,000.00 was provided by the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to the University of Colorado-Denver to develop "hemostatic red blood cells" (T-RBCs) that can bind to collagen and fibrin to enhance clot formation and stability. The goal is to create a novel technology to address severe, non-compressible bleeding, which is a major cause of mortality worldwide, especially in low-resource settings. The...

Federal Project Grant Award Summary Award Details: The National Heart, Lung, and Blood Institute (NHLBI) awarded Emprime Therapeutics Inc. a Project Grant of $314,363 under the Cardiovascular Diseases Research program (CFDA 93.837) on September 15, 2025, with completion targeted for August 31, 2026. Products and Services: This award funds the development of STITCHR, a novel dual adeno-associated virus (AAV) vector technology designed to deliver and express full-length Factor VIII (FVIII) for...

This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $151,523 to The Medical College of Wisconsin, Inc. to investigate the role of fibrinogen in regulating inflammation and thrombus resolution in acute and chronic venous thrombosis. The research aims to develop a novel RNA therapy using lipid nanoparticles to selectively reduce circulating fibrinogen levels and elucidate its impact on thromboinflammatory processes....